MegaStream proposes AIDD 3.0 dual-native model, with the first 5 pipelines advancing to IND filing

MegaStream TechBio, an AI-driven innovative drug R&D company jointly founded by Harbour BioMed and BioMap, recently appeared at the "2026 International Biocomputing Innovation Summit." During the summit, MegaStream held a strategic cooperation agreement signing ceremony with its two co-founders, marking the substantive implementation of MegaStream's effort to reshape the drug discovery paradigm with the "AIDD 3.0: AI×Bio dual-native" concept. With new Chief Executive Officer Lei Ming and Head of AI Chen Binbin joining the management team, MegaStream is continuing to advance the construction of its AI technology platform and the development of innovative drug pipelines, accelerating the translation of the "AI×Bio dual-native" concept into substantive innovative therapies that benefit patients worldwide. "We believe that the core competitiveness in the second half of AI drug discovery is not just the models themselves, but high-quality proprietary data, understanding of disease biology, model engineering capabilities, large-scale experimental validation capabilities, and the industrialization capability to continuously advance candidate molecules into clinical development," said Lei Ming. "Whether a repeatable and verifiable R&D closed loop can be formed is the key to distinguishing technology demonstrations from real drug R&D capabilities." In Lei Ming's view, AI drug discovery is gradually evolving from a stage dominated by algorithms and tool applications to a new stage of deep integration between AI and biological R&D, oriented toward real R&D outcomes and clinical value. This process can be summarized as three stages: AIDD 1.0, 2.0, and 3.0. 1.0 is "traditional pharmaceutical company R&D processes + AI tools," in which AI mainly assists single-point R&D links such as target analysis, molecule screening, or property prediction, while the overall R&D process remains dominated by the traditional drug R&D system. 2.0 is an AI-native enterprise or an R&D model centered on algorithms and models, in which model capabilities are further enhanced, but sufficient connections between model design and wet experiments or clinical feedback often have not yet been formed. 3.0 is dual-native AI and biotechnology, in which model R&D, dry and wet experiments, and drug development continuously iterate within the same system; experimental and subsequent development data can feed back into models, driving continuous evolution of R&D capabilities and further extending to clinical translation. MegaStream is positioning itself in AIDD 3.0. The company was jointly initiated by BioMap and Harbour BioMed, integrating BioMap's life science foundation models and AI engineering capabilities with Harbour BioMed's accumulated fully human antibody data, target biology, complex antibody R&D, and clinical development capabilities. MegaStream OS builds its core platform around target discovery (ID), molecule generation and optimization (Gen), and immunogenicity engineering (Immune), and forms a data feedback loop through wet-lab experimental validation. During the summit, MegaStream held a strategic cooperation agreement signing ceremony together with Harbour BioMed and BioMap. This major signing not only marks that the three parties will engage in deep collaboration in the fields of biocomputing and innovative drug R&D, but also signals that the integration of AI technology and life sciences will enter a new stage of substantive implementation. As co-founders of MegaStream, Harbour BioMed and BioMap announced in June 2026 the establishment of a long-term comprehensive strategic partnership and jointly initiated the founding of MegaStream, aiming to integrate "exclusive big data × proprietary large models × a large innovative pipeline portfolio" to build a new AI pipeline R&D company targeting the global market. Among them, Harbour BioMed will act as the lead initiator, opening to MegaStream its globally unique fully human antibody platform, deep target biology accumulation, and global clinical development advantages; BioMap will act as a co-initiator, providing underlying AI technology empowerment, model engineering support, and intelligent R&D capabilities to help the company rapidly advance its pipeline R&D process. Lei Ming said that the company has currently advanced the first batch of five innovative pipelines, some AI-designed molecules have achieved preliminary experimental validation progress, and the first project's IND filing target is the first half of 2027.